scholarly article | Q13442814 |
P50 | author | David E Spaner | Q92186816 |
P2093 | author name string | Yonghong Shi | |
Hubert Tsui | |||
Lindsay McCaw | |||
Guizhei Wang | |||
P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data | Q31096565 | ||
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production | Q33335197 | ||
Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1 | Q33374619 | ||
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis | Q33417004 | ||
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Q33437373 | ||
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial | Q33438420 | ||
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants | Q35822277 | ||
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. | Q36118340 | ||
Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback | Q36238033 | ||
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia | Q36743899 | ||
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study | Q36759124 | ||
Dose escalation methods in phase I cancer clinical trials | Q37198192 | ||
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells | Q37209768 | ||
Assessing splenomegaly: automated volumetric analysis of the spleen | Q37622042 | ||
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling | Q38069567 | ||
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases | Q38159870 | ||
Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. | Q38867757 | ||
miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer | Q38944644 | ||
Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. | Q40477812 | ||
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial | Q42399878 | ||
Ibrutinib treatment improves T cell number and function in CLL patients | Q42909982 | ||
Ibrutinib-resistant CLL: unwanted and unwonted! | Q48114125 | ||
Life after ibrutinib? A new unmet need in CLL. | Q48210951 | ||
IL-4 enhances expression and function of surface IgM in CLL cells. | Q55026394 | ||
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia | Q57169180 | ||
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib | Q58593499 | ||
In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO) | Q68707975 | ||
Recombinant PDGF enhances megakaryocytopoiesis in vitro | Q70861840 | ||
Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis | Q77768132 | ||
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent | Q78846264 | ||
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia | Q83128977 | ||
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells | Q91272438 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
phase I clinical trial | Q5452194 | ||
ibrutinib | Q5984881 | ||
platelet formation | Q14914622 | ||
P304 | page(s) | 1540-1550 | |
P577 | publication date | 2019-03-07 | |
P1433 | published in | Cancer Medicine | Q27724564 |
P1476 | title | Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial | |
P478 | volume | 8 |
Search more.